Hallmarks of cancer cell development

Genome stability in potentially immortal planarian stem cells

Global horizons of the WIN consortium

What is the WIN Consortium?

Pembrolizumab and indoximod for melanoma

Projections of cancer incidence and burden among the HIV-positive population in the United States through 2030

Nivolumab for NSCLC: five years on

Nivolumab and ipilimumab combination for advanced skin cancer

Long-term clinical outcomes and analyses of atezolizumab for mTNBC

Checkmate 067 - combined nivolumab and ipilimumab

Glycemia positively associated with prostate cancer mortality in non-diabetic men

IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors